EFPIA Transparency

The European Federation of Pharmaceutical Industries and Associations (EFPIA) and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with Healthcare Professionals (HCPs), Healthcare Organizations (HCOs), and Patient Organizations (POs) meet the high standards of integrity and transparency. As a member of the Roche group, Spark® Therapeutics supports the principles of transparency put forth by EFPIA and discloses payments to HCPs, HCOs, and POs where required under the EFPIA Code of Practice.

Patient Organizations

Spark® applies high ethical standards in all collaborations with patients and patient groups, including patient associations, patient advocacy groups, patient communities, patient experts, family members, and caregivers.

Patients are our guiding force. We strive to understand their individual journeys and unique needs. As we work to advance our pipeline of investigational therapies, we recognize the essential need to gain important perspectives from patients, families and leaders in patient advocacy. We respect the independence of patient groups, and the need to be transparent in our communications.

Financial support to POs may include membership fees, sponsorships, or charitable donations to support an organization’s core activities. The below link contains information on the support Spark provided to POs in EFPIA countries. It follows the standards set out in the EFPIA Code of Practice.

Starting with 2022 calendar year data and going forward, Spark’s PO data is included in Roche’s transparency disclosures:

https://www.roche.com/about/sustainability/collaboration-with-patients/groups/

Spark’s EFPIA Disclosure Reports

Spark is committed to the research, development, and production of treatments for genetic diseases. To achieve our goals, Spark collaborates with HCPs and HCOs who possess experience, knowledge, and vision complementary to that of our scientists. Collaboration with HCPs and HCOs contributes to the development of innovative medicines and to the achievement of important medical advances for patients.

As a member of the Roche group, Spark discloses relevant transfers of value to HCPs and HCOs made in the European Union in accordance with the EFPIA Disclosure Code. This includes, for example, HCP consultancy fees and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.

Click on the relevant link below to view Spark’s EFPIA disclosure reports and Methodological Notes. Starting with 2022 calendar year data and going forward, Spark’s transfers of value in EFPIA countries are included within each of Roche’s local affiliate disclosures.

Country	Year	Report	Methodological Note
Austria	2020	EFPIA Disclosure	Methodological Note
Belgium	2020	Consult the register	Methodological Note
	2021	Consult the register	Methodological Note
France	2020	Public health database	Methodological Note
	2021	Public health database	Methodological Note
Germany	2020	EFPIA Disclosure	Methodological Note
	2021	EFPIA Disclosure	Methodological Note
Ireland	2021	EFPIA Disclosure	Methodological Note
Italy	2020	EFPIA Disclosure	Methodological Note
	2021	EFPIA Disclosure	Methodological Note
Netherlands	2020	EFPIA Disclosure	Methodological Note
	2021	EFPIA Disclosure	Methodological Note
Spain	2020	EFPIA Disclosure	Methodological Note
	2021	EFPIA Disclosure	Methodological Note
Switzerland	2020	Support for Patient Organizations	Methodological Note
	2021	Support for Patient Organizations	Methodological Note